An observational study in Atherosclerosis, Cardiovascular Diseases and Heart Diseases, sponsored by Tulane University. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Tulane University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.
Among the 468 studies in Atherosclerosis with a site in United States, this one is the 7th largest by enrollment of the 137 observational ones that give a count, is the only one that started in 1973, is one of 137 observational ones, reaches primary completion later than 69 of the 70 other live ones, and was the 18th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 55+
Eli Lilly and Company · Sites in United States
Ages 18–70
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
468 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 84 · Phase 3 74 · Phase 4 45
First in 1973; this study’s year is marked. 1 started in 1973.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11,737 is above the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 119 across the 328 interventional studies, 170 across the 137 observational. Of the 366 that completed or were terminated, 134 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 468 have an industry lead sponsor. The 10 most frequent:
Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Tulane University has 2 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Atherosclerosis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07121010University of PittsburghHow Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 468 studies in Atherosclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the natural history of atherosclerosis, coronary artery disease, and hypertension in children and adults from birth through mid-life in a total biracial community.
BACKGROUND:
The Bogalusa Heart Study has been a long-term epidemiologic study. The investigators have identified and followed black and white participants for nearly 40 years, and have described the incidence and prevalence of biologic and behavioral cardiovascular disease risk factors from childhood through adulthood. Their participation has enabled the study to not only document differences between males and females, but also between blacks and whites. The results from the Bogalusa Heart Study have clearly documented that the genesis of atherosclerosis has its basis in childhood, and that prevention can and must begin at the early ages.
The Bogalusa Heart Study had been funded over the years by the Specialized Centers of Research (SCOR) Program. The SCOR program was initiated by NHLBI in 1970 to expedite the development and application of new knowledge essential for improved diagnosis, treatment, and prevention of arteriosclerosis, hypertension, pulmonary disease, and thrombosis. In 1984 a Demonstration and Education Component was added to the parent SCOR of the Bogalusa Heart Study in order to translate the experience gained in epidemiological studies into an intervention study designed to retard the development of cardiovascular risk factors in children. Beginning in 1987, the Bogalusa Heart Study was supported by a regular research grant. Beginning in 1997, the study is supported by the cooperative agreement mechanism.
DESIGN :
The initial survey in 1973-1974 was restricted to children ages 2 1/2 to 14. A physical examination was conducted and information was collected on anthropometric data, hemoglobin, blood pressure, serum lipids, and health history. Over 3,500 children participated. The second cross-sectional survey of 1976-1977 and subsequent surveys expanded the eligible population to include all children ages 5-17 years. The second survey of over 4,000 children also included information on salt intake, smoking, health beliefs, and attitudes, and for girls ages 8-17, menstrual history and oral contraceptive use. The third survey of over 3,500 participants in 1978-1979 also collected anthropometric measurements on skinfold thickness and two measurements of heart rate. The fourth survey of over 3,300 participants in 1981-1982 added data on alcohol use, Type A behavior, peer networks and dieting habits.
The Bogalusa Heart Study continued to use a cross-sectional and longitudinal design with the general cross-sectional survey of approximately 3,700 Bogalusa children ages five to seventeen in 1988-1989 in the sixth screen and additional longitudinal studies to recall children in defined subgroups for more intensive evaluation. Half of the 12,000 participants screened since 1973 had been studied three or more times. There were several other cohort groups and studies. The Newborn-Infant Cohort Study was designed to describe distributions, inter-relationships, and trends through time for blood pressure, serum lipid and lipoprotein concentrations, dietary intake patterns, and anthropometric measurements. Four hundred and forty infants born between January 1, 1974 through June 30, 1975 were examined at birth, at six months, and yearly at ages one through four and at seven, ten and thirteen years for cardiovascular risk factor variables. The Post High School Study examined young adults ages 21 through 30 who previously were examined as children ages five through fourteen in the first Bogalusa Heart Study screening in 1973-1974. The population included approximately 4,603 young adults originally screened and any other children or adolescents examined for the first time in any subsequent surveys.
The fifth screening began in 1988 and extended through December 1991. The Pediatric Pathology Risk Factor Program, which began in 1978, documented the relationship of cardiovascular disease risk factors to anatomic and pathologic changes. A local information system was established to obtain family or coroner's consent to autopsy any deceased resident between the ages of three and 26 in the Bogalusa area. Autopsy specimens were collected from over 100 deceased children and young adults, of whom approximately forty percent had been previously examined in the Bogalusa Heart Study.
Major activity during 1988-1991 involved 24-hour dietary recall collections on all the 1963, 1966, and 1968 birth cohorts attending the Post High School Study. A food frequency questionnaire was also self-administered to all the Post High School Study participants. The use of these two dietary methodologies, 24-hour dietary recall and food frequency questionnaire, provided data to assess the nutrient composition of diets of young adults, assess the weekly consumption of individual foods, compare nutrient composition data with food frequency data, and compare dietary intakes at the post high school age with those of school age. Several substudies were conducted using the Bogalusa Heart Study population. Among them were the impact of childhood obesity on risk factors, the relationship of apolipoproteins A-I and B in children to parental myocardial infarction and the relationship between left ventricular size as demonstrated by echocardiography and blood pressure distribution.
The study was renewed in Fiscal Year 1992 in order to follow-up the previously examined young adults for development of abnormal levels of cardiovascular risk factors and even clinical disease.
In 1997, the study was renewed and extended through 2002, and from 2002-2010, and again in 2012 in order to study the impact of genetic factors on the evolution from childhood cardiovascular risk factors to subclinical and clinical morbidity in an adult population, ages 20 to 43, who had been followed over a long period of time. The study also seeks to study the association of risk factor phenotypes to anatomic changes in the cardiovascular system as seen by necropsy. The population for genotype-phenotype studies includes approximately 1,400 siblings derived from longitudinal birth cohorts.
The cardiovascular phenotypes include obesity, blood pressure, lipids, lipoproteins, apoproteins, homocysteine, glucose-insulin, fibrinogen, plasminogen activator inhibitor-1 and von Willebrand Factor. Environmental risk factors consist of sociodemographic characteristics, tobacco and alcohol use, oral contraception, physical activity, cognitive and physical function, and quality of sleep and diet. Subclinical morbidity includes echo-Doppler measurements of cardiac-carotid structure and function. Using robust sibling pair linkage methods, a genome-wide search involving 391 markers with spacing of 10 centimorgans is conducted for genes which influence quantitative traits. This is supplemented with 41 highly polymorphic markers located in or near candidate genes likely to be related to obesity, lipoprotein metabolism, blood pressure, insulin resistance, diabetes, atherogenesis and thrombosis.
Approximately 75 percent of the dollars of a Specialized Center of Research (SCOR) in Arteriosclerosis (P50HL14103) were used to support the Bogalusa Heart Study from 1972 through 1986.
Since 2002, the study has been supported by the National Institute on Aging (NIA), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Environmental Health Sciences (NIEHS), and the National Institute of Child Health and Human Development (NICHD).
Approximately 12,000 individuals have ever been examined at least once. Approximately 6,000 have more than one examination constituting a dynamic cohort. Between 2014 and 2019, 3,550 were contacted for CV events follow-up.
Index individuals were identified as those living in Bogalusa, Louisiana between 1972 and 2000 who attended Bogalusa City Schools in childhood. The families of index individuals were eligible to participate in certain sub-studies e.g. sibling and parent studies. After 2000, only previously examined individuals and, in limited circumstances, their offspring, were eligible for participation in on-going follow-up of heart disease risk factors and related outcomes.
Brain health measured by brain MRI
The investigators will assess brain health by performing a brain MRI for each participant. The investigators will assess total cortical brain matter volume to determine brain health status.
Time frame: Up to 70 years
Atherosclerosis assessed by ultrasonography
Subclinical atherosclerosis will be assessed using ultrasonography to measure intima-media thickness (IMT) of the common carotid artery. Greater levels of IMT will indicate greater wall thickness, a risk factor for atherosclerosis.
Time frame: Up to 70 years
Myocardial infarction incidence
Cardiovascular disease outcomes will be assessed using longitudinal cardiovascular event data collected via a questionnaire during follow-up. Information will be collected on myocardial infarction incidence, which is self-reported. Event occurrence will be documented by the date of the event.
Time frame: Up to 70 years
Stroke incidence
Cardiovascular disease outcomes will be assessed using longitudinal cardiovascular event data collected via a questionnaire during follow-up. Information will be collected on stroke incidence, which is self-reported. Event occurrence will be documented by the date of the event.
Time frame: Up to 70 years
Heart failure incidence
Cardiovascular disease outcomes will be assessed using longitudinal cardiovascular event data collected via a questionnaire during follow-up. Information will be collected on heart failure incidence, which is self-reported. Event occurrence will be documented by the date of the event.
Time frame: Up to 70 years
Heart disease presence measured by echocardiography
Cardiac structure and function will be assessed using two-dimensional echocardiography. Measures will include ventricular mass and measures of ventricular function. The measures will be used as indicators of heart disease.
Time frame: Up to 70 years
Coronary disease presence documented by coronary exclusive events incidence
Coronary disease will be assessed using cardiovascular event information collected during longitudinal follow-up. Information will be collected on coronary-exclusive events, which are self-reported. Event occurrence will be documented by the event date.
Time frame: Up to 70 years
Hypertension incidence
Blood pressure will be measured during clinical examinations, including systolic and diastolic blood pressure, which are self-reported. Higher systolic and diastolic levels will indicate increased blood pressure. Standard clinical thresholds will be used to indicate hypertension.
Time frame: Up to 70 years
Plan to share: Yes — NHLBI Biolink
Started Aug 1973 (actual). Primary completion is estimated for Nov 2040, 807 months after the start.
Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 807 months is above that.
Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Nov 2029 → Nov 2040 and completion Nov 2029 → Nov 2040.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tulane University